Monday, April 24, 2023 8:39:39 AM
THER STOCK CANCER GOOD NEWS
BUY Ther
.meme stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
BUY Ther
.meme stock
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
Recent IDYA News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/23/2026 08:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2026 08:31:03 PM
- IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors • PR Newswire (US) • 06/17/2026 10:00:00 AM
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers • PR Newswire (US) • 06/15/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2026 08:10:24 PM
- IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 06/10/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/09/2026 09:16:39 PM
- IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 06/09/2026 02:22:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/08/2026 08:13:41 PM
- IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 06/08/2026 08:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2026 06:06:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2026 10:01:45 AM
- IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer • PR Newswire (US) • 06/03/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 08:05:32 PM
- IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO • PR Newswire (US) • 06/01/2026 03:00:00 PM
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/29/2026 10:00:00 AM
- IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference • PR Newswire (US) • 05/26/2026 10:00:00 AM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (US) • 05/18/2026 06:22:00 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (Canada) • 05/18/2026 06:22:00 PM
- A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology • GlobeNewswire Inc. • 05/14/2026 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 09:21:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/05/2026 09:19:31 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/05/2026 08:27:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:05:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 10:05:42 AM
